

‘Availability of Treatments by Province & Territory for Hepatitis C’

Province	Date of information	Rebetron (combo) Ifn-alpha2b+ribavirin Schering	Pegatron (combo) Peg-ifn2b+ribavirin Schering	Pegasys (mono) Peg-ifn2a Roche	Pegasys/Copegus Peg-ifn2a + ribavirin Roche (Interm CDR)	Particulars/Comments
BC	Jan. 04	Special authorization, Geno. 2/3 -24 wks.	Special authorization, TN (treatment naïve), Geno. 2/3 -24 wks.	Under review	Health Canada NOC approval applied for in Aug/02-still waiting despite 'fast track' process. Not submitted to province yet.	ALT 1.5x normal, 2x over 6 mos.
AB	Sept. 03	Special authorization	Special authorization Unitron also available	Under review	Not submitted yet	Anti-HCV, HCV-PCR, ALT/AST or biopsy results. Provincial drug plan has no premiums for over 65
Sask	Sept. 03	Exception Drug Status (EDS)	EDS, Unitron also available	Under review	Not submitted yet	Coverage for 6 mo. w/ potential 2 more 6 mo. periods of coverage
MB	Sept. 03	EDS	Part 3 EDS Doctor must be ID'd by MB gov't as familiar with treating HCV	Under review	Not covered	Dr. must provide genotype, ALT, biopsy, viral load, previous tx
ON	Oct. 03	Written, Physician, Section 8	Written, Physician, Section 8	Written, Physician, Section 8 *	Not submitted yet	Member TDP, Pay 4% household net income up front
PQ	Mar. 04	Up to 48 wks. Genotype 2/3 -24 wks.	Up to 48 wks. Genotype 2/3 -24 wks.	Under review		

NB/PEI				Under review		Same as Nova Scotia?
NS	Nov. 03		TN, Specialist written request	Under review	Not submitted yet	
NL	Aug. 03	Written/ph./fax request from infectious disease specialist	Written/ph./fax request from infectious disease specialist	Under review		
Yu	Aug. 03	Special authorization	Special authorization, TN	Under review	Not submitted yet	ALT 1.5x normal, 2x over 6 mos.
NWT				Under review		
Nu	Aug. 03			Under review		Paid for on a pre-approval basis depending on the policies in place in the larger jurisdictions.
FNIB				Covered (Individual approval)		

More copies of this pamphlet can be downloaded from: www.hepcure.ca

REBETRON® Combo (interferon alfa-2b + ribavirin/Schering Corporation)

UNITRON (R) Monotherapy (peginterferon alfa-2b/Schering Corporation) **PEG (TM)** or **PEG INTRON** in the USA.

PEGETRON (TM) Combo (peginterferon alfa-2b + ribavirin/Schering Corporation) in the USA is **REBETOL (R)**

PEGASYS Monotherapy (peginterferon alfa-2a/Hoffmann-La Roche, Inc.) in Canada

COPEGUS (Roche ribavirin) is awaiting approval in Canada.

***Ribavirin may be available under Roche's Ribavirin Access Program (RAP)**

